Onco Wiki / Enfermedad

Meningioma

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDDIS-MENINGIOMA
TipoEnfermedad
Aliaces
WHO grade I/II/III meningiomameningioma anaplásicoMeningioma atípicomeningioma intracranealMeningioma espinalМенінгіома
Situaciónreviewed 2026-05-04 | pending_clinical_signoff
EnfermedadesNinguna declarada
FuentesSRC-EANO-MENINGIOMA-2024 SRC-NCCN-CNS-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Fuente YAML

icd_o_3_morphology9530/0
icd_o_3_topography["C70"]
icd_10D32
who_classificationWHO Classification of Tumours of the CNS 5th ed (2021): Meningioma (grades 1–3)

Capacidades

Notas

Most meningiomas are WHO grade I (benign) and cured by gross total resection. Grade II (atypical) and grade III (anaplastic) have high recurrence rates and limited systemic options. NF2 loss is the most common molecular event; NF2-associated meningiomas often harbor co-occurring SMARCB1/SMARCA4 alterations in aggressive subtypes. Targeted therapy: AKT1-mutant meningioma → AKT inhibitors (capivasertib, ipatasertib) in phase II trials. SMO-mutant meningioma → vismodegib (case series). Selumetinib for NF2-associated plexiform neurofibroma has shown activity (FDA-approved in NF1 pediatric context) but NF2-meningioma selumetinib data is limited. Hormonal agents (progesterone receptor antagonists) not proven effective in trials. Bevacizumab used off-label for recurrent/progressive grade II-III based on small trials.

Utilizado por

Relevancia terapéutica

Algoritmos

Indicación

Procedimientos

Cuestionarios

Señal de alerta